相关实验视频
Updated: May 10, 2026

19:50
Interview: Protein Folding and Studies of Neurodegenerative Diseases
Published on: July 16, 2008
一个世纪以来关于蛋白质聚合和神经退行症的争论进入了临床
Peter T Lansbury1, Hilal A Lashuel
1Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, 65 Landsdowne Street, Cambridge, Massachusetts 02139, USA. lansbury@rics.bwh.harvard.edu
Nature
|October 20, 2006
概括
研究人员正在研究蛋白质聚合和神经退行性疾病 (如阿尔茨海默氏症) 之间的联系. 抑制蛋白质凝聚的药物的临床试验很快可能会澄清因果关系,并提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 神经退行性疾病与大脑中的蛋白质聚合之间存在强烈的相关性.
- 由于这些疾病的复杂性和识别特定病原性聚合物的困难,建立明确的因果关系一直是具有挑战性的.
研究的目的:
- 探索蛋白质聚合和神经退行性疾病之间的关系.
- 评估聚合抑制药物在临床环境中的潜力.
- 为了解决长期存在的蛋白质错折障碍的因果关系问题.
主要方法:
- 审查当前对神经退行性疾病中蛋白质聚合的理解.
- 对正在进行的聚合抑制候选药物临床试验的分析.
- 讨论临床试验结果对疾病因果关系的影响.
主要成果:
- 虽然直接的因果关系仍然难以捉摸,但在了解蛋白质聚合方面取得了重大进展.
- 旨在抑制蛋白质聚合的候选药物目前正在接受临床评估.
- 这些试验代表了潜在验证蛋白质聚合物在疾病发病过程中的作用的关键一步.
结论:
- 抑制蛋白质聚合有望减缓阿尔茨海默氏症和帕金森症等疾病的进展.
- 这些药物的症状前给药可以显著降低疾病发生率.
- 临床试验有望解决关于蛋白质聚合在神经退行症中的因果作用的辩论.
相关概念视频
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

